2 hours Needham & Company LLC Reaffirms “Buy” Rating for Cartesian Therapeutics (NASDAQ:RNAC)MarketBeat
Needham & Company LLC restated a “buy” rating and set a $41.00 target price on shares of Cartesian Therapeutics in a report on Wednesday.
XNeedham & Company LLC restated a “buy” rating and set a $41.00 target price on shares of Cartesian Therapeutics in a report on Wednesday.
X